AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

5,570.00p
   
  • Change Today:
      60.00p
  • 52 Week High: 6,317.00
  • 52 Week Low: 4,712.50
  • Currency: UK Pounds
  • Shares Issued: 1,267.04m
  • Volume: 2,733,252
  • Market Cap: £70,574m
  • RiskGrade: 122
  • Beta: 0.01

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (18-01-2019)

1 Day Chart

6 Month Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 3.9% 3.9%
Div Cover 1.5 1.2
Op Mrgn 18.2% 23.3%
ROCE 465.6%  
Latest F'cast
P/E 16.8 20.9
PEG n/a n/a
Pr/Revenue 4.5 4.1
Pr/Book 5.5  
Latest F'cast
Revenue -5.5% -33.9%
PBT -37.3% 39.2%
EPS -0.7% -20.4%
DPS n/a -39.4%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-13 25,711.00 3,267.00 505.00¢ 9.1 n/a -26% 280.00¢ 6.1%
31-Dec-14 26,095.00 1,246.00 428.00¢ 13.7 n/a -15% 280.00¢ 4.8%
31-Dec-15 23,641.00 3,069.00 426.00¢ 13.9 n/a -0% 280.00¢ 4.7%
31-Dec-16 21,319.00 3,552.00 431.00¢ 13.2 13.2 +1% 280.00¢ 4.9%
31-Dec-17 20,152.00 2,227.00 428.00¢ 15.4 n/a -1% 280.00¢ 4.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-18 17,126.04 3,988.44 264.93p 21.0 n/a -20% 218.35p 3.9%
31-Dec-19 18,204.49 4,323.51 280.57p 19.9 3.4 +6% 219.99p 3.9%
31-Dec-20 20,146.08 5,077.82 354.40p 15.7 0.6 +26% 224.77p 4.0%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

AstraZeneca announces organisational changes 07-Jan-2019 13:00 RNS
Total Voting Rights 02-Jan-2019 15:00 RNS
Bevespi Aerosphere approved in the EU for COPD 20-Dec-2018 13:47 RNS

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 5,570.00p
Change Today 60.00p
% Change 1.09 %
52 Week High 6,317.00
52 Week Low 4,712.50
Volume 2,733,252
Shares Issued 1,267.04m
Market Cap £70,574m
Beta 0.01
RiskGrade 122

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
21.41% below the market average21.41% below the market average21.41% below the market average21.41% below the market average21.41% below the market average
82.46% above the sector average82.46% above the sector average82.46% above the sector average82.46% above the sector average82.46% above the sector average
Price Trend
79.72% above the market average79.72% above the market average79.72% above the market average79.72% above the market average79.72% above the market average
76.27% above the sector average76.27% above the sector average76.27% above the sector average76.27% above the sector average76.27% above the sector average
Income
21.58% above the market average21.58% above the market average21.58% above the market average21.58% above the market average21.58% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Growth
82.75% below the market average82.75% below the market average82.75% below the market average82.75% below the market average82.75% below the market average
89.47% below the sector average89.47% below the sector average89.47% below the sector average89.47% below the sector average89.47% below the sector average

What The Brokers Say

Strong Buy 16
Buy 2
Neutral 11
Sell 1
Strong Sell 2
Total 32
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-19 28-Feb-19
Paid 09-Sep-19 27-Mar-19
Amount 90.00¢ 190.00¢

Trades for 18-Jan-2019

Time Volume / Share Price
16:36 1,152 @ 5,570.00p
16:36 5,000 @ 5,570.00p
16:35 5,000 @ 5,570.00p
16:35 1,028,155 @ 5,570.00p
16:30 231 @ 5,578.00p

Top of Page